BCYC
Bicycle Therapeutics PLC
Price:  
7.10 
USD
Volume:  
210,802.00
United Kingdom | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

BCYC WACC - Weighted Average Cost of Capital

The WACC of Bicycle Therapeutics PLC (BCYC) is 8.6%.

The Cost of Equity of Bicycle Therapeutics PLC (BCYC) is 8.55%.
The Cost of Debt of Bicycle Therapeutics PLC (BCYC) is 8.55%.

Range Selected
Cost of equity 6.90% - 10.20% 8.55%
Tax rate 1.40% - 1.80% 1.60%
Cost of debt 7.00% - 10.10% 8.55%
WACC 6.9% - 10.2% 8.6%
WACC

BCYC WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 0.66 0.96
Additional risk adjustments 0.0% 0.5%
Cost of equity 6.90% 10.20%
Tax rate 1.40% 1.80%
Debt/Equity ratio 0 0
Cost of debt 7.00% 10.10%
After-tax WACC 6.9% 10.2%
Selected WACC 8.6%

BCYC's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for BCYC:

cost_of_equity (8.55%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (0.66) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.